No material news briefings were available for AbbVie Inc. in the current reporting cycle. The prior cycle's brief, dated 24 May 2026, noted AbbVie's trailing twelve-month revenue through 31 March 2026 [Brief - 2026-05-24]. This report is grounded in regulatory filings, ownership disclosures, and macroeconomic data as detailed below.
AbbVie's trailing twelve-month revenue through 31 March 2026 stood at $62.82 billion, reflecting year-over-year growth of 12.4%. Net income for the same period was $3.64 billion, producing a net margin of 5.79%. Gross margin was recorded at 67.4% and operating margin at 24.4%. EPS declined 45.8% year-over-year. The company held $9.39 billion in cash against total debt of $64.50 billion. The trailing P/E ratio stood at 107.25 [SEC 10-Q - ABBV - 2026-03-31].
Insider activity over the past 30 days comprised 11 transactions with a mixed directional profile and a net reported value of zero, indicating no dominant buy or dispose pattern among insiders [SEC Form 4 - ABBV - 2026-06]. At the institutional level, notable position changes were filed in the most recent 13F cycle. Millennium Management added 61% to its position, and Bridgewater Associates added 114% to its position. Conversely, Citadel reduced its position by 11%, and AQR Capital reduced its position by 23% [SEC 13F - Millennium - Q1 2026] [SEC 13F - Bridgewater - Q1 2026] [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026].
The broader macroeconomic backdrop as of the report date shows the 10-year US Treasury yield at 4.45% and the 2-year yield at 3.99%, producing a normal yield curve with a spread of 46 basis points [FRED DGS10] [FRED DGS2]. This interest rate environment is relevant context for AbbVie given the company's total debt position of $64.50 billion, as prevailing borrowing costs factor into debt servicing dynamics.
This report was generated in response to material institutional position changes identified in the most recent 13F filings, specifically the divergent activity among large quantitative and macro-oriented funds as detailed in the holdings section above.